articleJournal of Clinical OncologyJan 9, 2024HYBRID OA

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

PRPriya RastogiJOJoyce O’ShaughnessyMMMiguel MartínFBFrances BoyleJCJavier Cortés

UPMC Hillman Cancer Center · NSABP Foundation · +24 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) that persisted beyond the 2-year treatment period in patients with hormone receptor–positive, human…

Citation impact

197
total citations
FWCI
72.84
Percentile
100%
References
16
Citations per year

Authors

23

Topics & keywords

Topics
Keywords
  • Medicine
  • Oncology
  • Breast cancer
  • Internal medicine
  • Hazard ratio
  • Interim analysis
  • Population
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding